Exhibit 99.1 individuals in the U.S. Existing therapies for these diseases today generally offer incomplete efficacy, meaningful safety warnings, and inconvenient dosing profiles. Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second quarter, with enrollment ...

On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second quarter, with enrollment continuing ahead of schedule Enrollment on track in Phase 2 SKYWAY basket trial evaluating TL1A inhibition in rheumatoid arthritis ("RA"), psoriatic arthritis ("PsA"), and axial spondyloarthritis ("axSpA"), with fourth quarter readouts expected in each sub-study Strengthened the balance ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _________________________________________________________ FORM 10-K _________________________________________________________ x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______ to Commission file number 001-37722 ___ ...

WALTHAM, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced scientific presentations at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO), held February 18-21, 2026 in Stockholm, Sweden. “We are excited to share follow-up data out to 20 weeks fro ...

Group 1 - Spyre Therapeutics (NASDAQ:SYRE) is identified as one of the 17 biotechnology stocks with more than 50% upside potential, with a projected median 1-year price target of $57.86, indicating an upside of over 66% [1] - The company has received coverage from 7 analysts, all of whom have assigned Buy ratings, reflecting a strongly bullish consensus sentiment [1] - As of January 22, 2026, Spyre Therapeutics plans to prioritize six proof-of-concept (POC) readouts, with the SKYLINE ulcerative colitis trial completing SPY001 enrollment ahead of schedule, and the SKYWAY basket trial on track for fourth-quarter readouts in 2026 [2] Group 2 - Financially, Spyre Therapeutics reported $783 million in pro forma cash, cash equivalents, and marketable securities as of September 30, 2025, providing a runway through the second half of 2028 [2] - The company is a clinical-stage biotechnology firm focused on developing advanced antibody therapeutics for inflammatory bowel disease (IBD), including conditions such as ulcerative colitis and Crohn's disease [3] - Spyre's current pipeline includes multiple candidates: SPY001, SPY002, SPY003, and various combination therapies [3]

Core Viewpoint - Spyre Therapeutics, Inc. (NASDAQ:SYRE) is recognized as one of the top stocks to buy, with strong buy ratings from multiple analysts and significant growth potential in its pipeline for treating inflammatory bowel disease (IBD) [1][2][4]. Group 1: Analyst Ratings and Price Targets - Wells Fargo has reiterated a Buy rating on SYRE with a price target of $40 [1]. - Mizuho initiated coverage with an Outperform rating and a price target of $53, highlighting the potential of the company's anti-monoclonal antibodies for IBD [2]. - Wall Street analysts have a consensus Strong Buy rating with an average one-year price target of $56.67, indicating a potential upside of 72.77% [4]. Group 2: Clinical Trials and Drug Development - Spyre Therapeutics reported positive results from its Phase 1 trial of SPY003, an extended half-life antibody for IBD, showing a half-life of nearly 85 days across 59 participants [3]. - The company is focused on developing treatments for inflammatory bowel and rheumatic diseases, which positions it well for future growth [5]. Group 3: Financial Performance - The company's shares have increased by over 69% in the last three months, driven by positive trial results and favorable analyst updates [5]. - The third-quarter results showed a significant reduction in net loss, decreasing from $69 million in the previous year to $11.2 million [5]. Group 4: Future Projections - Mizuho projects that Spyre Therapeutics' global sales could reach $1.7 billion by 2035, indicating strong long-term growth potential [4].

Core Insights - Spyre Therapeutics is set to deliver six proof-of-concept readouts in 2026 from its SKYLINE and SKYWAY trials, focusing on inflammatory bowel disease and rheumatic diseases [2][3] - The company has appointed Kate Tansey Chevlen as Chief Commercial Officer, bringing extensive experience from Amgen to enhance its commercial strategy [2][7][8] Group 1: Trial Updates - The SKYLINE platform trial for ulcerative colitis is progressing faster than anticipated, with SPY001 enrollment completed ahead of schedule and Part A readouts expected to begin in Q2 2026 [1][4] - The SKYWAY basket trial is on track, with enrollment ongoing across rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, with all readouts anticipated in Q4 2026 [1][5] Group 2: Financial Position - As of September 30, 2025, Spyre Therapeutics reported a strong balance sheet with pro forma cash, cash equivalents, and marketable securities totaling $783 million, providing a cash runway into the second half of 2028 [2][9] Group 3: Leadership and Strategy - The appointment of Kate Tansey Chevlen as CCO is expected to significantly contribute to the company's Phase 3 strategy and product uptake, leveraging her nearly two decades of experience in biopharma [3][8] - The company aims to redefine the standard of care for inflammatory bowel disease and rheumatic diseases with its innovative long-acting antibodies and combinations [2][10]

Company Overview - Spyre Therapeutics is a preclinical biotechnology company specializing in innovative antibody-based therapies for inflammatory bowel disease (IBD) [7] - The company focuses on novel mechanisms and combination biologics to address significant unmet needs in gastrointestinal medicine [7] - Spyre Therapeutics has a robust pipeline and expertise in monoclonal antibody development, aiming to establish a competitive edge in the IBD therapeutic landscape [7] Financial Metrics - The company's market capitalization is $2.3 billion [6] - Spyre Therapeutics has 73 employees [6] - The net income for the trailing twelve months (TTM) is -$127.7 million [6] - The stock price as of market close on January 2 was $30.58 [6] Recent Insider Activity - CEO Cameron Turtle sold 15,000 shares on January 2 for a total consideration of approximately $460,134 [2][3] - After the sale, Turtle retained about 671,907 shares valued at approximately $20.5 million [5] - The 15,000-share sale accounted for 2.2% of Turtle's direct ownership [8] Stock Performance - Over the past year through January 9, Spyre Therapeutics' shares gained 36.3%, outperforming the Nasdaq Composite's total return of 24.3% [11]

Core Insights - The biotech industry is characterized by a combination of scientific innovation and financial instability among many companies [1] Group 1: Industry Characteristics - The biotech sector often features clinical stage companies that are high-growth but face precarious financial situations [1] - There is a strong inclination towards investing in sectors that are expected to experience exponential growth [1] Group 2: Investment Approach - The investment strategy focuses on understanding and investing in disruptive technologies and forward-thinking enterprises [1] - The approach combines fundamental analysis with predictions of future trends, emphasizing the potential of innovation to generate substantial returns [1]

Core Insights - Several small- and mid-cap stocks experienced notable gains in after-hours trading, driven by investor sentiment and sector momentum rather than new company news [1][2][3][4][5] Company Summaries - **Spyre Therapeutics, Inc. (SYRE)**: Closed at $34.71, up $1.65 or 4.99%, leading the list of gainers despite no new updates [1] - **The Oncology Institute, Inc. (TOI)**: Ended at $3.65, up $0.19 or 5.49%, with steady share price increase without new announcements [2] - **Aurora Cannabis Inc. (ACB)**: Closed at $5.70, gaining $0.13 or 2.33%, benefiting from renewed momentum in the cannabis sector [2] - **Solid Biosciences Inc. (SLDB)**: Finished at $5.45, up $0.07 or 1.30%, supported by the recent addition of Duchenne muscular dystrophy to the Recommended Uniform Screening Panel [3] - **EUDA Health Holdings Limited (EUDA)**: Closed at $2.74, gaining $0.12 or 4.58%, attracting buyers in after-hours trading [4] - **Lexeo Therapeutics, Inc. (LXEO)**: Ended at $9.50, up $0.39 or 4.28%, continuing a trend of strength in the biotech sector [4] - **Eledon Pharmaceuticals, Inc. (ELDN)**: Closed at $1.59, up $0.02 or 1.27%, managing a modest gain without new news [5]